Infect Chemother.  2008 Feb;40(1):49-51. 10.3947/ic.2008.40.1.49.

In Vitro Susceptibility of piperacillin/tazobactam Against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae

• Kim EC

• KMID: 1483477
• DOI: http://doi.org/10.3947/ic.2008.40.1.49

Abstract

Minimal inhibitory concentrations (MIC) of piperacillin/tazobactam were determined on 20 clinical isolates of extended-spectrum beta-lactamase (ESBL)-producing E. coli and 30 isolates of ESBL- producing Klebsiella pneumoniae. MIC50 and MIC90 for ESBL-producing E. coli were 8/4 microg/ml and 256/4 microg/mL, respectively. MIC50 and MIC90 for ESBL-producing K. pneumoniae were 8/4 microg/mL and > 512/4 microg/mL, respectively. The susceptibilities of ESBL-producing E. coli and K. pneumoniae to piperacillin/tazobactam were 80% and 60%, respectively. Of 20 ESBL-producing E. coli strains, 11 (55%) were TEM-and CTX-M-positive, and SHV-negative. Of 30 ESBL-producing K. pneumoniae strains, ten (33%) were PCR positive for SHV and negative for TEM and CTX-M.

Keyword

Piperacillin/tazobactam; ESBL-producing E. coli; ESBL-producing K. pneumoniae

MeSH Terms

beta-Lactamases
Escherichia
Escherichia coli
Klebsiella
Klebsiella pneumoniae
Pneumonia
Polymerase Chain Reaction
beta-Lactamases

Figure

• 

  Fig. 1 MIC cumulative percentage curves of piperacillin/tazobactam. Abbreviations: ECO, E. coli, KPN, K. pneumoniae.

Reference

1. Gavin PJ, Suseno MT, Thomson RB Jr, Gaydos JM, Pierson CL, Halstead DC, Aslanzadeh J, Brecher S, Rotstein C, Brossette SE, Peterson LR. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother. 2006. 50:2244–2247.

2. Lee J, Pai H, Kim YK, Kim NH, Eun BW, Kang HJ, Park KH, Choi EH, Shin HY, Kim EC, Lee HJ, Ahn HS. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy. J Antimicrob Chemother. 2007. 60:629–637.

3. Shin HJ, Jang YS, Seo MR, Pai HJ, Ahn MJ, Lee YY, Choi TY. Impact of Piperacillin/Tazobactam Use to Intestinal Colonization of Extended-spectrum-lactamase Producing Escherichia coli and Klebsiella pneumoniae. Infect Chemother. 2007. 39:65–70.

4. Brahmi N, Blel Y, Kouraichi N, Lahdhiri S, Thabet H, Hedhili A, Amamou M. Impact of ceftazidime restriction on gram-negative bacterial resistance in an intensive care unit. J Infect Chemother. 2006. 12:190–194.

5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. CLSI document. 2007. 7th. Wayne, PA: CLSI;M100–S17. .

6. Clinical and Laboratory Standards Institute. Methods for dilution Antimicrobial susceptibility tests for bacteria that grow aerobically. CLSI document. 2006. 7th. Wayne, PA: CLSI;M7–A7. .

7. Schmitt J, Jacobs E, Schmidt H. Molecular characterization of extended-spectrum beta-lactamases in Enterobacteriaceae from patients of two hospitals in Saxony, Germany. J Med Microbiol. 2007. 56:241–249.

8. Dutour C, Bonnet R, Marchandin H, Boyer M, Chanal C, Sirot D, Sirot J. CTX-M-1, CTX-M-3, and CTX-M-14 beta-lactamases from Enterobacteriaceae isolated in France. Antimicrob Agents Chemother. 2002. 46:534–537.